Stoke Therapeutics, Inc.
STOK
$31.16
-$1.34-4.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -437.70% | 92.26% | 138.47% | 150.68% | 146.32% |
| Total Depreciation and Amortization | -17.17% | -18.70% | -16.88% | -16.15% | -14.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.77% | 22.29% | 12.55% | 10.53% | 8.83% |
| Change in Net Operating Assets | -29.11% | 158.09% | -135.38% | -285.56% | -144.34% |
| Cash from Operations | -311.13% | 152.49% | 162.68% | 177.04% | 182.52% |
| Capital Expenditure | -153.94% | -230.05% | -23.08% | 32.69% | 76.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -43.86% | -73.52% | -33.63% | -239.15% | -260.92% |
| Cash from Investing | -44.22% | -73.82% | -33.58% | -235.43% | -265.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37.93% | -25.71% | -95.93% | -91.82% | 1,252.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 37.93% | -25.71% | -95.93% | -91.82% | 1,252.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -220.50% | 30.67% | -66.34% | -6,581.50% | 920.39% |